ZA9810490B - 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor - Google Patents

2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor

Info

Publication number
ZA9810490B
ZA9810490B ZA9810490A ZA9810490A ZA9810490B ZA 9810490 B ZA9810490 B ZA 9810490B ZA 9810490 A ZA9810490 A ZA 9810490A ZA 9810490 A ZA9810490 A ZA 9810490A ZA 9810490 B ZA9810490 B ZA 9810490B
Authority
ZA
South Africa
Prior art keywords
aryl
preparation
pharmaceutical composition
composition containing
same
Prior art date
Application number
ZA9810490A
Other languages
English (en)
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of ZA9810490B publication Critical patent/ZA9810490B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
ZA9810490A 1997-12-03 1998-11-17 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor ZA9810490B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03

Publications (1)

Publication Number Publication Date
ZA9810490B true ZA9810490B (en) 1999-05-20

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810490A ZA9810490B (en) 1997-12-03 1998-11-17 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor

Country Status (27)

Country Link
US (1) US6372740B1 (fr)
EP (1) EP1036794B1 (fr)
JP (1) JP3815966B2 (fr)
KR (1) KR100494347B1 (fr)
CN (1) CN1146566C (fr)
AR (1) AR017796A1 (fr)
AT (1) ATE248169T1 (fr)
AU (1) AU744014B2 (fr)
BR (1) BR9815140A (fr)
CA (1) CA2312885C (fr)
DE (1) DE69817611T2 (fr)
DK (1) DK1036794T3 (fr)
ES (1) ES2205574T3 (fr)
HK (1) HK1028769A1 (fr)
HU (1) HUP0004422A3 (fr)
ID (1) ID24929A (fr)
IL (1) IL135920A0 (fr)
NO (1) NO20002835L (fr)
NZ (1) NZ504457A (fr)
PL (1) PL191489B1 (fr)
PT (1) PT1036794E (fr)
RU (1) RU2223272C2 (fr)
SK (1) SK285703B6 (fr)
TR (1) TR200001600T2 (fr)
TW (1) TW502034B (fr)
WO (1) WO1999028320A1 (fr)
ZA (1) ZA9810490B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073306A1 (fr) * 1999-05-31 2000-12-07 Dainippon Pharmaceutical Co., Ltd. Derives de 2-arylpurine-9-acetamide, leur procede de preparation, compositions medicinales les contenant et intermediaires des derives

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
CN1399632A (zh) * 1999-09-27 2003-02-26 小野药品工业株式会社 嘧啶衍生物、其制备方法和含有该化合物作为有效成分的药物
WO2002010167A1 (fr) * 2000-07-31 2002-02-07 Dainippon Pharmaceutical Co., Ltd. Medicaments contre la demence contenant des derives de 2-aryl-8-oxodihydropurine comme ingredient actif
CA2554566A1 (fr) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Composes de pyramidine condenses utilises comme inhibiteurs de canaux ioniques potentiel-dependants
CA2554774A1 (fr) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Nouveau compose heterocyclique
WO2005115399A2 (fr) * 2004-04-16 2005-12-08 Neurogen Corporation Imidazopyrazines, imidazopyridines, et imidazopyrimidines utilisees comme ligands du recepteur crf1
FR2870239B1 (fr) 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
NZ562468A (en) * 2005-04-05 2009-10-30 Pharmacopeia Inc Purine and imidazopyridine derivatives for immunosuppression
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7951803B2 (en) * 2006-03-09 2011-05-31 Pharmacopeia, Llc 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
AR063142A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043019A1 (fr) * 2006-10-04 2008-04-10 Pharmacopeia, Inc Dérivés de 2-(benzimidazolyl) purine substitués en position 8 pour immunosuppression
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
CN102656172B (zh) * 2009-09-09 2016-03-23 大日本住友制药株式会社 8-氧代二氢嘌呤衍生物
EP2493472B1 (fr) 2009-10-26 2016-12-07 Signal Pharmaceuticals, LLC Procédés de synthèse et de purification de composés hétéroaryles
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
WO2012168697A1 (fr) 2011-06-06 2012-12-13 Imperial Innovations Limited Procédés de prédiction de l'affinité de liaison à tspo d'agents d'imagerie
CN107157990B (zh) 2011-10-19 2020-01-07 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
UA114496C2 (uk) 2011-12-02 2017-06-26 Сігнал Фармасьютікалз, Елелсі ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ 7-(6-(2-ГІДРОКСИПРОПАН-2-ІЛ)ПІРИДИН-3-ІЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГІДРОПІРАЗИНО[2,3-b]ПІРАЗИН-2(1H)-ОНУ, ЇХ ТВЕРДІ ФОРМИ І СПОСОБИ ЇХ ЗАСТОСУВАННЯ
EA028462B1 (ru) 2012-02-24 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
BR112015016997A2 (pt) 2013-01-16 2017-07-11 Signal Pharm Llc composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
CA2908353C (fr) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
JP6382948B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014172426A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131551A4 (fr) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160882A1 (fr) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Formes solides comprenant de la 7-(6- (2-hydroxypropan-2-yl) pyridin-3-yl)-1-(trans)-4-méthoxycyclohexyl)-3, 4-dihydropyrazino[2,3-b] pyrazin-2(1h)-one, et un co-formeur, leurs compositions et leurs procédés d'utilisation
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
SG11201804098TA (en) 2015-11-20 2018-06-28 Forma Therapeutics Inc Purinones as ubiquitin-specific protease 1 inhibitors
JP7282045B2 (ja) 2017-06-22 2023-05-26 セルジーン コーポレイション Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療
EP3752505B1 (fr) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Nouveaux composés et dérivés de sulfone pour le traitement et la prophylaxie d'une infection virale

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US6028076A (en) 1996-07-03 2000-02-22 Japan Energy Corporation Purine derivative
NZ335823A (en) * 1997-04-22 2001-06-29 Neurocrine Biosciences Inc Thiophenopyridines, preparation as CRF receptor antagonists
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073306A1 (fr) * 1999-05-31 2000-12-07 Dainippon Pharmaceutical Co., Ltd. Derives de 2-arylpurine-9-acetamide, leur procede de preparation, compositions medicinales les contenant et intermediaires des derives

Also Published As

Publication number Publication date
EP1036794A1 (fr) 2000-09-20
PL340925A1 (en) 2001-03-12
US6372740B1 (en) 2002-04-16
SK7972000A3 (en) 2001-03-12
AU744014B2 (en) 2002-02-14
EP1036794A4 (fr) 2001-12-12
DE69817611T2 (de) 2004-02-26
CN1146566C (zh) 2004-04-21
NZ504457A (en) 2001-12-21
WO1999028320A1 (fr) 1999-06-10
TW502034B (en) 2002-09-11
HUP0004422A3 (en) 2001-10-29
HUP0004422A2 (hu) 2001-04-28
DE69817611D1 (de) 2003-10-02
SK285703B6 (sk) 2007-06-07
DK1036794T3 (da) 2003-12-22
CN1284076A (zh) 2001-02-14
CA2312885A1 (fr) 1999-06-10
ATE248169T1 (de) 2003-09-15
TR200001600T2 (tr) 2000-11-21
AU1260499A (en) 1999-06-16
JP3815966B2 (ja) 2006-08-30
NO20002835L (no) 2000-07-24
ID24929A (id) 2000-08-31
AR017796A1 (es) 2001-10-24
CA2312885C (fr) 2008-01-29
ES2205574T3 (es) 2004-05-01
HK1028769A1 (en) 2001-03-02
RU2223272C2 (ru) 2004-02-10
BR9815140A (pt) 2000-10-10
EP1036794B1 (fr) 2003-08-27
KR100494347B1 (ko) 2005-06-13
PL191489B1 (pl) 2006-05-31
NO20002835D0 (no) 2000-06-02
PT1036794E (pt) 2003-11-28
KR20010032686A (ko) 2001-04-25
IL135920A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
ZA9810490B (en) 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HU9601698D0 (en) Pharmaceutical composition
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
IL113103A0 (en) Piperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
ZA962214B (en) Pharmaceutical composition
GB9519667D0 (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
IL115272A0 (en) Asp-pallidipin pharmaceutical compositions containing the same and processes for the preparation thereof
GB9502695D0 (en) Pharmaceutical composition
ZA9610426B (en) Pharmaceutical composition
HUP0104544A3 (en) New pharmaceutical composition and the process for its preparation
IL115981A (en) Cyclolignan derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0003463A3 (en) Piperidinylmethyloxazolidinone derivative, process for its preparation pharmaceutical compositions containing it and use thereof
HU9602822D0 (en) Pharmaceutical composition
HUP9602732A3 (en) Pharmaceutical composition comprising lanperisone
ZA95736B (en) Pharmaceutical composition
GB9414183D0 (en) Pharmaceutical composition
HU9400523D0 (en) Pharmaceutical composition
GB9405024D0 (en) Pharmaceutical composition
GB9420991D0 (en) Pharmaceutical composition
GB9405025D0 (en) Pharmaceutical composition
ZA953965B (en) Pharmaceutical composition
GB9414182D0 (en) Pharmaceutical composition